Suppr超能文献

鼻腔鼻窦中线的 NUT 癌。

NUT midline carcinomas of the sinonasal tract.

机构信息

Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.

出版信息

Am J Surg Pathol. 2012 Aug;36(8):1216-21. doi: 10.1097/PAS.0b013e318254ce54.

Abstract

NUT midline carcinoma (NMC) is a highly lethal tumor defined by translocations involving the NUT gene on chromosome 15q14. NMC involves midline structures including the sinonasal tract, but its overall incidence at this midline site and its full morphologic profile are largely unknown because sinonasal tumors are not routinely tested for the NUT gene translocation. The recent availability of an immunohistochemical probe for the NUT protein now permits a more complete characterization of sinonasal NMCs. The archival files of The Johns Hopkins Hospital Surgical Pathology were searched for all cases of primary sinonasal carcinomas diagnosed from 1995 to 2011. Tissue microarrays were constructed, and NUT immunohistochemical analysis was performed. All NUT-positive cases underwent a more detailed microscopic and immunohistochemical analysis. Among 151 primary sinonasal carcinomas, only 3 (2%) were NUT positive. NUT positivity was detected in 2 of 13 (15%) carcinomas diagnosed as sinonasal undifferentiated carcinoma and in 1 of 87 (1%) carcinomas diagnosed as squamous cell carcinoma. All occurred in men (26, 33, and 48 y of age). The NMCs grew as nests and sheets of cells with a high mitotic rate and extensive necrosis. Two were entirely undifferentiated, and 1 tumor showed abrupt areas of squamous differentiation. Each case had areas of cell spindling, and 2 were heavily infiltrated by neutrophils. Immunohistochemical staining was observed for cytokeratins (3 of 3), epithelial membrane antigen (3 of 3), p63 (2 of 3), CD34 (1 of 3), and synaptophysin (1 of 3). All patients died of the disease (survival time range, 8 to 16 mo; mean, 12 mo) despite combined surgery and chemoradiation. NMC represents a rare form of primary sinonasal carcinoma, but its incidence is significantly increased in those carcinomas that exhibit an undifferentiated component. Indiscriminant analysis for evidence of the NUT translocation is unwarranted. Instead, NUT analysis can be restricted to those carcinomas that demonstrate undifferentiated areas. The availability of an immunohistochemical probe has greatly facilitated this analysis and is helping to define the full demographic, morphologic, and immunohistochemical spectrum of sinonasal NMC.

摘要

NUT 中线癌(NMC)是一种具有高度致死性的肿瘤,其特征是染色体 15q14 上的 NUT 基因发生易位。NMC 涉及中线结构,包括鼻-鼻窦道,但由于鼻-鼻窦肿瘤通常不进行 NUT 基因易位检测,因此中线部位的总体发生率及其完整的形态学特征尚不清楚。最近,一种用于 NUT 蛋白的免疫组化探针的出现,使得对鼻-鼻窦 NMC 的更全面特征描述成为可能。检索约翰霍普金斯医院外科病理学存档文件,查找 1995 年至 2011 年期间诊断的所有原发性鼻-鼻窦癌病例。构建组织微阵列,并进行 NUT 免疫组化分析。所有 NUT 阳性病例均进行更详细的显微镜和免疫组化分析。在 151 例原发性鼻-鼻窦癌中,只有 3 例(2%)为 NUT 阳性。在 13 例诊断为鼻-鼻窦未分化癌的病例中检测到 2 例(15%)和在 87 例诊断为鳞状细胞癌的病例中检测到 1 例(1%)NUT 阳性。所有病例均为男性(26、33 和 48 岁)。NMC 呈巢状和片状生长,有较高的有丝分裂率和广泛的坏死。2 例完全未分化,1 例肿瘤突然出现鳞状分化区域。每个病例均有细胞梭形区域,其中 2 例被中性粒细胞重度浸润。免疫组化染色观察到细胞角蛋白(3 例中的 3 例)、上皮膜抗原(3 例中的 3 例)、p63(3 例中的 2 例)、CD34(3 例中的 1 例)和突触素(3 例中的 1 例)。所有患者均死于疾病(生存时间 8 至 16 个月;平均 12 个月),尽管接受了手术和放化疗联合治疗。NMC 代表一种罕见的原发性鼻-鼻窦癌,但在表现出未分化成分的癌中,其发生率显著增加。无鉴别地分析 NUT 易位的证据是没有必要的。相反,可以将 NUT 分析仅限于那些表现出未分化区域的癌。免疫组化探针的可用性极大地促进了这种分析,并有助于确定鼻-鼻窦 NMC 的完整人口统计学、形态学和免疫组化特征。

相似文献

1
NUT midline carcinomas of the sinonasal tract.
Am J Surg Pathol. 2012 Aug;36(8):1216-21. doi: 10.1097/PAS.0b013e318254ce54.
2
[Utility of NUT gene expression and rearrangement in diagnosis of NUT midline carcinoma in upper respiratory tract].
Zhonghua Bing Li Xue Za Zhi. 2012 Aug;41(8):519-24. doi: 10.3760/cma.j.issn.0529-5807.2012.08.003.
3
Clinicopathological significance of NUT rearrangements in poorly differentiated malignant tumors of the upper respiratory tract.
Int J Surg Pathol. 2013 Apr;21(2):102-10. doi: 10.1177/1066896912451651. Epub 2012 Jul 9.
4
NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract.
Am J Surg Pathol. 2008 Jun;32(6):828-34. doi: 10.1097/PAS.0b013e31815a3900.
5
Cytopathologic features of NUT midline carcinoma: A series of 26 specimens from 13 patients.
Cancer Cytopathol. 2016 Dec;124(12):901-908. doi: 10.1002/cncy.21761. Epub 2016 Jul 11.
8
Demystified molecular pathology of NUT midline carcinomas.
J Clin Pathol. 2010 Jun;63(6):492-6. doi: 10.1136/jcp.2007.052902. Epub 2008 Jun 13.
10
NUT midline carcinoma of the larynx: an international series and review of the literature.
Histopathology. 2017 May;70(6):861-868. doi: 10.1111/his.13143. Epub 2017 Feb 21.

引用本文的文献

1
EGFR mutations in sinonasal squamous neoplasms: Novel hotspot for exon 20 insertions.
Virchows Arch. 2025 Mar 13. doi: 10.1007/s00428-025-04070-0.
2
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck.
Nat Rev Clin Oncol. 2025 Apr;22(4):292-306. doi: 10.1038/s41571-025-00986-3. Epub 2025 Feb 3.
3
Metastatic SMARCA4-deficient undifferentiated tumor in the small mesentery: case report.
World J Surg Oncol. 2024 Dec 20;22(1):337. doi: 10.1186/s12957-024-03619-8.
4
Clinical analysis and treatment progress of NUT carcinoma in the nasal cavity and sinuses: a retrospective study from a single institution.
Eur Arch Otorhinolaryngol. 2025 Jan;282(1):377-386. doi: 10.1007/s00405-024-08898-1. Epub 2024 Aug 17.
5
The histological spectrum and immunoprofile of head and neck NUT carcinoma: A multicentre series of 30 cases.
Histopathology. 2024 Aug;85(2):317-326. doi: 10.1111/his.15204. Epub 2024 May 6.
6
Maxillary Sinus NUT Carcinoma: A Case Report.
Cancer Diagn Progn. 2024 May 3;4(3):370-378. doi: 10.21873/cdp.10334. eCollection 2024 May-Jun.
7
A Rare Case of P63-Negative Sinonasal Nut Midline Carcinoma in the Elderly.
Eur J Case Rep Intern Med. 2024 Jan 17;11(2):004265. doi: 10.12890/2024_004265. eCollection 2024.
8
Therapeutic approaches to sinonasal NUT carcinoma: a systematic review.
Eur Arch Otorhinolaryngol. 2024 Jul;281(7):3361-3369. doi: 10.1007/s00405-024-08489-0. Epub 2024 Feb 8.
9
Clinicopathological molecular characterizations of sinonasal NUT carcinoma: a report of two cases and a literature review.
Front Oncol. 2024 Jan 4;13:1296862. doi: 10.3389/fonc.2023.1296862. eCollection 2023.
10
The Role of Gene Fusions in Thymic Epithelial Tumors.
Cancers (Basel). 2023 Nov 27;15(23):5596. doi: 10.3390/cancers15235596.

本文引用的文献

1
Nuclear protein in testis midline carcinomas: a lethal and underrecognized entity.
Arch Pathol Lab Med. 2011 Nov;135(11):1494-8. doi: 10.5858/arpa.2010-0389-CR.
2
Pathogenesis of NUT midline carcinoma.
Annu Rev Pathol. 2012;7:247-65. doi: 10.1146/annurev-pathol-011811-132438. Epub 2011 Oct 17.
3
Differentiation of NUT midline carcinoma by epigenomic reprogramming.
Cancer Res. 2011 Apr 1;71(7):2686-96. doi: 10.1158/0008-5472.CAN-10-3513. Epub 2011 Mar 29.
4
A review of NUT midline carcinoma.
Head Neck Pathol. 2011 Mar;5(1):31-5. doi: 10.1007/s12105-010-0235-x. Epub 2011 Jan 8.
5
Selective inhibition of BET bromodomains.
Nature. 2010 Dec 23;468(7327):1067-73. doi: 10.1038/nature09504. Epub 2010 Sep 24.
6
NUT midline carcinoma: case report and review of the literature.
Int J Surg Pathol. 2011 Dec;19(6):808-12. doi: 10.1177/1066896909353600. Epub 2009 Dec 24.
7
NUT midline carcinoma in a newborn with multiorgan disseminated tumor and a 2-year-old with a pancreatic/hepatic primary.
Pediatr Dev Pathol. 2010 Nov-Dec;13(6):481-5. doi: 10.2350/09-10-0727-CR.1. Epub 2009 Dec 17.
8
Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody.
Am J Surg Pathol. 2009 Jul;33(7):984-91. doi: 10.1097/PAS.0b013e318198d666.
9
p63 Expression in olfactory neuroblastoma and other small cell tumors of the sinonasal tract.
Am J Clin Pathol. 2008 Aug;130(2):213-8. doi: 10.1309/TEDD2FCWH8W0H4HA.
10
Demystified molecular pathology of NUT midline carcinomas.
J Clin Pathol. 2010 Jun;63(6):492-6. doi: 10.1136/jcp.2007.052902. Epub 2008 Jun 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验